Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial

OBJECTIVE: Patients with refractory status epilepticus (RSE) have failed treatment with benzodiazepines and ≥1 second‐line intravenous (IV) antiseizure medication (ASM). Guidelines recommend IV anesthesia when second‐line ASMs have failed, but potential harms can outweigh the benefits. Novel treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaitkevicius, Henrikas, Ramsay, R. Eugene, Swisher, Christa B., Husain, Aatif M., Aimetti, Alex, Gasior, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796093/
https://www.ncbi.nlm.nih.gov/pubmed/35748707
http://dx.doi.org/10.1111/epi.17343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796093/
https://www.ncbi.nlm.nih.gov/pubmed/35748707
http://dx.doi.org/10.1111/epi.17343

Ejemplares similares